Aptevo Therapeutics

Aptevo Advances APVO711: Novel Bispecific Antibody Combining PD-L1 Checkpoint Inhibition with CD40 Immune Activation

15 days ago

• Aptevo Therapeutics has announced progress on APVO711, a dual-mechanism bispecific antibody that simultaneously blocks PD-L1 and activates CD40, potentially overcoming resistance to standard checkpoint inhibitors. • Preclinical studies demonstrate APVO711's ability to both block immune suppression and enhance T-cell priming, showing promise for treating a wide range of solid tumors resistant to current immunotherapies. • The development of APVO711 showcases Aptevo's ADAPTIR platform capabilities while complementing their clinical-stage pipeline, which includes mipletamig for AML and ALG.APV-527 for solid tumors.

Sunshine Biopharma Launches Generic Everolimus in Canada's $2.5B Oncology Market

a month ago

• Sunshine Biopharma's Canadian subsidiary, Nora Pharma Inc., has introduced generic Everolimus to the Canadian market, targeting multiple cancer indications including advanced renal cell carcinoma and breast cancer. • The global Everolimus market, valued at $2.5 billion in 2023, is projected to reach $4.8 billion by 2032 with a CAGR of 7.1%, while the Canadian segment grows at 6.4% annually. • Sunshine Biopharma continues expanding its portfolio of 70 generic drugs with 15 additional launches planned for 2025, including NIOPEG®, a biosimilar of NEULASTA® for reducing infection in cancer patients.

Aptevo Therapeutics Secures $2.1 Million in Financing to Advance Immune-Oncology Pipeline

2 months ago

• Aptevo Therapeutics has closed a $2.1 million financing through a registered direct offering and concurrent private placement priced at $1.19 per share. • The clinical-stage biotech will use proceeds to advance its pipeline of novel immune-oncology therapeutics, including mipletamig for acute myeloid leukemia and ALG.APV-527 for solid tumors. • The financing includes 1,764,710 shares of common stock and warrants to purchase up to 3,529,420 additional shares, with Roth Capital Partners serving as the exclusive placement agent.

Aptevo's ALG.APV-527 Shows Promise in Solid Tumors with Favorable Safety Profile in Phase 1 Trial

3 months ago

• Phase 1 dose escalation study of ALG.APV-527 demonstrates disease stabilization in 59% of evaluable patients across multiple solid tumor types, with notable durability in breast, colon, and prostate cancers. • The bispecific antibody shows a favorable safety profile with limited liver toxicity, a common concern with similar therapeutics, potentially differentiating it from competitors. • The drug, co-developed with Alligator Bioscience, targets 4-1BB and 5T4, offering a novel approach for treating various solid tumors including NSCLC, breast, and colorectal cancers.

Aptevo's Mipletamig Achieves 100% Remission Rate in Frontline AML Trial

5 months ago

• Aptevo Therapeutics' mipletamig, combined with venetoclax and azacitidine, achieved a 100% remission rate within 30 days in Cohort 1 of the RAINIER trial for frontline AML. • Two out of three patients in Cohort 1 attained complete remission with minimal residual disease (MRD)-negative status, indicating complete cancer cell elimination. • One MRD-negative patient had a TP53 mutation, which is typically associated with poor prognosis, showcasing the drug's potential in difficult-to-treat AML. • Enrollment for Cohort 2 of the RAINIER trial has commenced, building on the favorable safety and tolerability profile observed in earlier studies.

ALG.APV-527 Bispecific Antibody Shows Promise in Phase 1 Solid Tumor Trial

6 months ago

• Aptevo Therapeutics and Alligator Bioscience's ALG.APV-527 met key Phase 1 trial endpoints for safety, tolerability, and biological activity in solid tumors. • 56% of evaluable patients achieved stable disease, including colon and breast cancer patients with durable responses over six and eleven months, respectively. • The bispecific antibody demonstrated a favorable safety profile, with no serious liver toxicity observed, differentiating it from other 4-1BB targeting treatments. • Biomarker analysis confirmed immune activation within the tumor microenvironment, supporting the drug's mechanism of action and potential as a cancer immunotherapy.